There has been plenty of chatter about whether GLP-1 drugs might be longevity drugs in disguise. A new study in Nature adds the most direct preclinical evidence yet: semaglutide extended lifespan in already-aged female mice.
The mice were 20 months old when treatment began, well into late life by laboratory standards. Semaglutide (a popular GLP-1 agonist) reduced the mice’s food intake and body weight, just like it does in humans. But the treated mice also lived longer, moved more, coordinated their movements better, maintained better glucose control, and performed better on tests of spatial memory.1
The survival result is the…
